Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 9/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.48 |
| ▸ | CALCA | P06881 | 2/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | GRPR | P30550 | 2/20 | 0.47 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955853 | 0.89 | ERBB2 (0.52) | ERBB2CCKBRCALCA | |
| SCHEMBL21955442 | 0.88 | DPP3 (0.47) | CCKBRCXCR4 | |
| SCHEMBL22984866 | 0.87 | CCKBR (0.49) | ERBB2CCKBRGRPR | |
| SCHEMBL23008651 | 0.85 | CCKBR (0.46) | CCKBRCXCR4 | |
| SCHEMBL22984879 | 0.84 | DPP3 (0.46) | CCKBRCXCR4IL23R | |
| SCHEMBL21956028 | 0.82 | IL23R (0.58) | CCKBRCXCR4CALCAIL23R | |
| SCHEMBL23008652 | 0.81 | DPP3 (0.47) | CCKBRCXCR4 | |
| SCHEMBL30435668 | 0.79 | GLP1R (0.59) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL21955405 | 0.79 | IL23R (0.64) | CCKBRIL23R | |
| SCHEMBL21955407 | 0.79 | IL23R (0.64) | CCKBRIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | ERBB2 261/4885CCKBR 17/4885CXCR4 55/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | ERBB2 261/4885CCKBR 17/4885CXCR4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.